(3aR,5R,6S,6aR)-6-(benzyloxy)-5-((benzyloxy)methyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxole-5-carbaldehyde | 233266-76-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3aR,5R,6S,6aR)-6-(benzyloxy)-5-((benzyloxy)methyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxole-5-carbaldehyde
• 英文别名: 3,5-di-O-benzyl-4-C-formyl-1,2-O-isopropylidene-α-D-ribo-pentofuranose；(3aR,5R,6S,6aR)-6-(benzyloxy)-5-(benzyloxymethyl)-2,2-dimethyl-tetrahydrofuro[2,3-d][1,3]dioxole-5-carbaldehyde；(3aR,5R,6S,6aR)-2,2-dimethyl-6-phenylmethoxy-5-(phenylmethoxymethyl)-6,6a-dihydro-3aH-furo[2,3-d][1,3]dioxole-5-carbaldehyde
• CAS: 233266-76-7
• 化学式: C₂₃H₂₆O₆
• 分子量: 398.456
• InChiKey: DFSYYZDXKFTDJV-BESBDSHLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  63.2
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (3aR,5R,6S,6aR)-6-(benzyloxy)-5-((benzyloxy)methyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxole-5-carbaldehyde 在 正丁基锂 、 三氟甲磺酸三甲基硅酯 、 溶剂黄146 、 三苯基膦 作用下， 以 四氢呋喃 、 吡啶 、 二氯甲烷 、 水 、 1,2-二氯乙烷 为溶剂， 生成 (2R,3R,4S,5R)-4-(benzyloxy)-5-((benzyloxy)methyl)-2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-5-((triethylsilyl)ethynyl)tetrahydrofuran-3-yl acetate
  参考文献：
  名称：

  Synthesis of 4′-C-Ethynyl-β-D-arabino- and 4′-C-Ethynyl-2′-deoxy-β-D-ribo- pentofuranosyl Pyrimidines, and Their Biological Evaluation

  摘要：

  4′-C-乙炔基-β-D-阿拉伯五碳呋喃糖胸腺嘧啶（14）和细胞嘧啶（16），以及4′-C-乙炔基-2′-脱氧-β-D-核糖五碳呋喃糖胸腺嘧啶（25）和细胞嘧啶（27）是通过适当保护的4′-C-羟甲基-3,5-二-O-苄基-α-D-核糖五碳呋喃糖（1）从D-葡萄糖合成的。其中，2′-脱氧衍生物25和27表现出了抗病毒活性，而胞苷衍生物16和27抑制了肿瘤细胞的生长。

  DOI：

  10.1271/bbb.63.1146
• 作为产物：
  描述：

  1,2:5,6-二异亚丙基-alpha-D-异呋喃糖 在 sodium periodate 、 草酰氯 、 sodium hydride 、 溶剂黄146 、 二甲基亚砜 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 、 乙腈 、 mineral oil 为溶剂， 反应 225.5h， 生成 (3aR,5R,6S,6aR)-6-(benzyloxy)-5-((benzyloxy)methyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxole-5-carbaldehyde
  参考文献：
  名称：

  Synthesis of 2′-O,4′-C-alkylene-bridged ribonucleosides and their evaluation as inhibitors of HCV NS5B polymerase

  摘要：

  The synthesis of 2'-O,4'-C-methylene-bridged bicyclic guanine ribonucleosides bearing 2'-C-methyl or 5'C-methyl modifications is described. Key to the successful installation of the methyl functionality in both cases was the use of a one-pot oxidation-Grignard procedure to avoid formation of the respective unreactive hydrates prior to alkylation. The 2'-C-methyl- and 5'-C-methyl-modified bicyclic guanosines were evaluated, along with the known uracil-, cytosine-, adenine-, guanine-LNA and guanine-ENA nucleosides, as potential antiviral agents and found to be inactive in the hepatitis C virus (HCV) cell-based replicon assay. Examination of the corresponding nucleoside triphosphates, however, against the purified HCV NS5B polymerase indicated that LNA-G and 2'-C-methyl-LNA-G are potent inhibitors of both 1b wild type and S282T mutant enzymes in vitro. Activity was further demonstrated for the LNA-G-triphosphate against HCV NS5B polymerase genotypes 1a, 2a, 3a and 4a. A phosphorylation by-pass prodrug strategy may be required to promote anti-HCV activity in the replicon assay. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.04.050

文献信息

• BRIDGED ARTIFICIAL NUCLEOSIDE AND NUCLEOTIDE
  申请人：Obika Satoshi

  公开号：US20120208991A1

  公开（公告）日：2012-08-16

  It is an object of the present invention to provide a novel molecule for antisense therapies which is not susceptible to nuclease degradation in vivo and has a high binding affinity and specificity for the target mRNAs and which can efficiently regulate expression of specific genes. The novel artificial nucleoside of the present invention has an amide bond introduced into a bridge structure of 2′,4′-BNA/LNA. The oligonucleotide containing the 2′,4′-bridged artificial nucleotide has a binding affinity for a single-stranded RNA comparable to known 2′,4′-BNA/LNA and has an increased nuclease resistance over LNA. Particularly, it is expected to be applied to nucleic acid drugs because of its much stronger binding affinity for single-stranded RNAs than S-oligo's affinity

  本发明的目的是提供一种新型分子用于反义疗法，该分子在体内不易受核酸酶降解，并且对目标mRNA具有高结合亲和力和特异性，能够有效调节特定基因的表达。本发明的新型人工核苷酸在2′,4′-BNA/LNA的桥接结构中引入了酰胺键。含有2′,4′-桥接人工核苷酸的寡核苷酸与已知的2′,4′-BNA/LNA具有相当的单链RNA结合亲和力，并且比LNA具有更高的核酸酶抗性。特别地，由于其比S-oligo对单链RNA的结合亲和力更强，预计将被应用于核酸药物。
• ヌクレオシド誘導体の製造方法
  申请人：国立大学法人岐阜大学

  公开号：JP2019119739A

  公开（公告）日：2019-07-22

  【課題】ＲＮＡ医薬等に適用するためのより実用的なヌクレオシド誘導体の製造方法の提供。【解決手段】下式の化合物１０などで表されるヌクレオチド誘導体の製造方法であって、１，２：５，６−ジ−Ｏ−イソプロピリデン−α−Ｄ−グルコフラノースから数工程を経て得られる下式の化合物９を、ウラシルと、ビス（トリメチルシリル）アセタミドで処理し、ヌクレオチド化合物１０を得る。【選択図】なし

  提供一种用于应用于RNA药物等的更实用的核苷酸衍生物的制备方法。采用下式化合物10等表示的核苷酸衍生物的制备方法，其中通过对1,2:5,6-二-O-异丙基亚-D-葡萄糖苷从而得到下式化合物9，然后与尿嘧啶、双(三甲基硅基)乙酰胺处理，得到核苷酸化合物10。【选择图】无
• 4′-C-ethynyl pyrimidine nucleoside compounds and pharmaceutical compositions
  申请人：Yamasa Corporation

  公开号：US06291670B1

  公开（公告）日：2001-09-18

  The invention provides 4′-C-ethynyl pyrimidine nucleosides (other than 4′-C-ethynylthymidine) represented by formula [I]: wherein B represents a base selected from the group consisting of pyrimidine and derivatives thereof; X represents a hydrogen atom or a hydroxyl group; and R represents a hydrogen atom or a phosphate residue; and a pharmaceutical composition containing any one of the compounds and a pharmaceutically acceptable carrier. Preferably, the composition is used as an anti-HIV agent or a drug for treating AIDS.

  该发明提供了由公式[I]表示的4'-C-乙炔嘧啶核苷（除了4'-C-乙炔胸腺嘧啶）：其中B代表从嘧啶及其衍生物组成的基；X代表氢原子或羟基；R代表氢原子或磷酸酯基团；以及含有任一化合物和药学上可接受的载体的药物组合物。最好，该组合物用作抗HIV药剂或治疗艾滋病的药物。
• Five- and Six-Membered Conformationally Locked 2‘,4‘-Carbocyclic <i>ribo</i>-Thymidines:  Synthesis, Structure, and Biochemical Studies
  作者：Puneet Srivastava、Jharna Barman、Wimal Pathmasiri、Oleksandr Plashkevych、Małgorzata Wenska、Jyoti Chattopadhyaya

  DOI：10.1021/ja071106y

  日期：2007.7.1

  radical center at C2' of the ribofuranose ring of thymidine have been used as key steps to synthesize North-type conformationally constrained cis-fused bicyclic five-membered and six-membered carbocyclic analogues of LNA (carbocyclic-LNA-T) and ENA (carbocyclic-ENA-T) in high yields. Their structures have been confirmed unambiguously by long range 1H-13C NMR correlation (HMBC), TOCSY, COSY, and NOE experiments

  两个不寻常的反应，包括 5-己烯基或 6-庚烯基自由基环化在 C4' 的远距离双键和 C2' 的胸苷核呋喃糖环的自由基中心已被用作合成 North 型构象限制顺式的关键步骤高产率的 LNA（碳环-LNA-T）和 ENA（碳环-ENA-T）的稠合双环五元和六元碳环类似物。它们的结构已通过长程 1H-13C NMR 相关 (HMBC)、TOCSY、COSY 和 NOE 实验得到明确证实。随后将碳环-LNA-T 和碳环-ENA-T 掺入反义寡核苷酸 (AON) 中，以表明它们将修饰的 AON/RNA 异源双链的 Tm 提高了 3.5-5 摄氏度和 1.5 摄氏度/碳环修饰-LNA-T 和碳环-ENA-T，分别。而发现碳环-LNA-T、碳环-ENA-T、氮杂-ENA-T和LNA-T修饰的AON/RNA双链体的相对RNase H切割率与天然对应物非常相似，无论AON 链中的类型和位点修饰，与天然的相比，将碳环-LNA
• Fine Tuning of Electrostatics around the Internucleotidic Phosphate through Incorporation of Modified 2′,4′-Carbocyclic-LNAs and -ENAs Leads to Significant Modulation of Antisense Properties
  作者：Chuanzheng Zhou、Yi Liu、Mounir Andaloussi、Naresh Badgujar、Oleksandr Plashkevych、Jyoti Chattopadhyaya

  DOI：10.1021/jo8016742

  日期：2009.1.2

  choice of the cleavage sites of RNase H mediated RNA cleavage in the AON/RNA hybrid duplex, but the cleavage rate depended on the modification site in the AON sequence. If the original preferred cleavage site by RNase H was included in the 4-5nt stretch from the 3′-end of the modification site in the AON, decreased cleavage rate was observed. Upon screening of 52 modified AONs, containing 13 differently

  在反义（AS）和RNA干扰（RNAi）技术中，对天然单链2'-脱氧寡核苷酸（用于AS）或双链RNA（用于RNAi）进行化学修饰，使其与目标RNA结合，从而获得更好的通过抑制RNA翻译来下调基因表达。此处显示了通过改变取代基的静电相互作用以及围绕反义寡核苷酸（AON）-RNA异源双链体的小树林边缘附近的核苷酸间磷酸二酯部分周围的立体化学环境的精细调节，如何导致调节反义性质。通过合成各种修饰的碳环锁核酸（LNA）和在碳环部分连接有羟基和/或甲基取代基的-亚乙基桥核酸（ENA）并通过固相DNA合成将其整合到AON中来证明这一点。 。这些修饰的AON对互补RNA和DNA的靶标亲和力，核酸酶抗性和RNase H诱导表明，修饰的性质（-OH与-CH3）及其相对于邻位磷酸盐的立体化学取向在调节AON特性方面起着非常重要的作用。尽管对靶RNA的亲和力和AONs的酶稳定性受小沟中心的疏水和空间大体积修饰的不